A detailed history of Bank Of America Corp transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 42,287 shares of GOSS stock, worth $37,635. This represents 0.0% of its overall portfolio holdings.

Number of Shares
42,287
Previous 119,966 64.75%
Holding current value
$37,635
Previous $141,000 73.05%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.51 - $1.27 $39,616 - $98,652
-77,679 Reduced 64.75%
42,287 $38,000
Q1 2024

May 15, 2024

BUY
$0.8 - $1.51 $30,608 - $57,774
38,261 Added 46.83%
119,966 $141,000
Q4 2023

Feb 14, 2024

SELL
$0.48 - $1.08 $10,644 - $23,950
-22,176 Reduced 21.35%
81,705 $74,000
Q2 2023

Aug 14, 2023

SELL
$0.98 - $1.53 $122,548 - $191,324
-125,049 Reduced 54.62%
103,881 $124,000
Q1 2023

May 12, 2023

SELL
$0.96 - $2.92 $2.7 Million - $8.22 Million
-2,814,377 Reduced 92.48%
228,930 $288,000
Q4 2022

Feb 10, 2023

BUY
$1.74 - $12.87 $4.67 Million - $34.6 Million
2,685,828 Added 751.32%
3,043,307 $6.6 Million
Q3 2022

Nov 14, 2022

SELL
$7.21 - $14.88 $687,423 - $1.42 Million
-95,343 Reduced 21.06%
357,479 $4.28 Million
Q2 2022

Aug 12, 2022

BUY
$5.97 - $9.97 $924,484 - $1.54 Million
154,855 Added 51.97%
452,822 $3.79 Million
Q1 2022

May 16, 2022

BUY
$8.44 - $12.49 $373,993 - $553,456
44,312 Added 17.47%
297,967 $2.59 Million
Q4 2021

Feb 08, 2022

BUY
$10.12 - $14.07 $1.62 Million - $2.25 Million
160,180 Added 171.36%
253,655 $2.87 Million
Q3 2021

Nov 15, 2021

BUY
$7.25 - $13.23 $145,036 - $264,666
20,005 Added 27.23%
93,475 $1.18 Million
Q2 2021

Sep 13, 2021

BUY
$8.0 - $9.75 $587,760 - $716,332
73,470 New
73,470 $597,000

Others Institutions Holding GOSS

About Gossamer Bio, Inc.


  • Ticker GOSS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,954,000
  • Market Cap $83.6M
  • Description
  • Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...
More about GOSS
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.